German court foils Novartis' gliptin AMNOG bid
This article was originally published in Scrip
Executive Summary
Novartis' attempt to block Germany from retrospectively assessing its gliptin Galvus crashed on 15 May as a German court promptly dismissed the suit, snuffing out hope for an escape from price cuts for all companies with marketed drugs in that class.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.